- Home
- UMBF vs CDTX Comparison
UMBF vs CDTX Comparison
Compare UMBF & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMBF | CDTX |
|---|---|---|
| Founded | 1913 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | UMBF | CDTX |
|---|---|---|
| Price | $119.01 | $220.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $136.27 | $128.75 |
| AVG Volume (30 Days) | 498.6K | ★ 947.6K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ 10.98 | N/A |
| EPS | ★ 8.89 | N/A |
| Revenue | ★ $2,217,071,000.00 | N/A |
| Revenue This Year | $69.52 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $13.37 | ★ N/A |
| Revenue Growth | ★ 45.52 | N/A |
| 52 Week Low | $82.00 | $15.22 |
| 52 Week High | $126.14 | $221.20 |
Technical Indicators
Market Signals| Indicator | UMBF | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 85.79 |
| Support Level | $118.17 | $219.91 |
| Resistance Level | $120.26 | $221.00 |
| Average True Range (ATR) | 2.24 | 0.54 |
| MACD | 0.02 | -3.90 |
| Stochastic Oscillator | 75.09 | 87.86 |
Price Performance
Historical ComparisonAbout UMBF UMB Financial Corporation
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.